9th RNA-Targeted Drug Discovery and Development Summit

RNA-targeting small molecules are rapidly gaining therapeutic traction, underscored by clinical advances including ReviR Therapeutics first participant dosed in a Phase 1 study of RTX-117 and Remix Therapeutics reporting positive Phase 1/2 data for REM-422. Building on the clinical validation of splice modulation, the field is progressing across direct RNA binding, RNA degradation, covalent translation inhibition, epitranscriptomic regulation and condensate biology, establishing RNA-targeted small molecules as an increasingly credible route to modulate disease biology once considered beyond the reach of conventional protein-targeted strategies.

With scientific innovation at the core of this momentum, the 9th RNA-Targeted Drug Discovery and Development Summit returns to Boston this November as the industry's only dedicated forum focused exclusively on RNA-targeted small molecules. Bringing together leaders from pioneering biotechs, major pharma and expert academia, including PTC Therapeutics, Remix Therapeutics, ReviR Therapeutics, AstraZeneca, Sanofi, Atomic AI, Syrna Therapeutics, Dewpoint Therapeutics, EPICS Therapeutics, Ribonaut Therapeutics and Ribometrix, the summit will deliver the latest data, practical discovery strategies and collaborative discussion shaping the future of RNA0targeted therapeutics.

With a refreshed agenda spanning functional RNA target selection, structure-guided design, productive chemical space, emerging RNA-targeting technologies, and translational considerations, this forum reaffirms its position as the go-to meeting for connecting the scientific and strategic decisions needed to progress RNA-targeted small molecules from discovery toward clinical impact.

URLs:
Website: https://go.evvnt.com/3684765-0?pid=2874
Brochure: https://go.evvnt.com/3684765-2?pid=2874

Category: Conferences | Science, Health and Medicine

Prices:
Drug Developer - Conference + Workshop Day: USD 4397.00,
Drug Developer - Conference Only: USD 3099.00,
Academic - Conference + Workshop Day: USD 3797.00,
Academic - Conference Only: USD 2699.00,
Service Provider - Conference + Workshop Day: USD 5297.00,
Service Provider - Conference Only: USD 3799.00

Speakers: Aaron Hoskins, Wasson Professor in Biochemistry, University of Wisconsin-Madison, Amanda Hargrove, Director and Professor - Medicinal Chemistry, University of Toronto, Andrea Casazza, Head of Cancer Biology, EPICS Therapeutics, Ann Boija, Senior Vice President, Head of Research, Dewpoint Therapeutics, Charlotte Henderson, Co-Founder and Chief Executive Officer, RevoNA Bio, Christopher Trotta, Senior Vice President of Discovery Biology, PTC Therapeutics, Dalya Gartzman, Chief Executive Officer, Renasis Bio, David Sparkman-Yager, Co-Founder and Chief Technology Officer, Wayfinder Biosciences, David Weitz, Chief Executive Officer and Founder, Syrna Therapeutics Inc, Domi Stickens, Chief Scientific Officer, Arrakis Therapeutics Inc., Dominic Reynolds, Chief Scientific Officer, Remix Therapeutics, Jennifer Petter, Founder and Former Chief Scientific Officer, Arrakis Therapeutics Inc., Kevin Weeks, Professor, Department of Chemistry, UNC at Chapel Hill, Lukasz Olenginski, Senior Scientist, Screening and Assay Development, Mol Horizon, Inc., Matt Smola, Associate Director - RNA Biology, Ribometrix, Nikolai Naryshkin, Chief Scientific Officer, Ribonaut Therapeutics, Paraskevi Gkeka, Distinguished Scientist, Group Head CADD, Sanofi, Raphael Townshend, Founder and Chief Executive Officer, Atomic AI, Robert Batey, Professor and Associate Chair of Graduate Affairs, University of Colorado Boulder, Scott Barraza, Associate Director, Early Discovery Chemistry, PTC Therapeutics, Sridhar Narayan, Vice President, Medicinal Chemistry, ReviR Therapeutics, Stefan Schiesser, Director - Medicinal Chemistry, AstraZeneca, Thomas Hermann, Co-Founder, Scientific Advisor and Board Director, Syrna Therapeutics Inc, Tom Chappie, Senior Principal Scientist and Research Fellow, Pfizer, Yann Foricher, Head of Small Molecules Medicinal Chemistry, Sanofi